B Cell Immunity in Lung Transplant Rejection - Effector Mechanisms and Therapeutic Implications.

Front Immunol

Department of Thoracic Surgery, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.

Published: May 2022

Allograft rejection remains the major hurdle in lung transplantation despite modern immunosuppressive treatment. As part of the alloreactive process, B cells are increasingly recognized as modulators of alloimmunity and initiators of a donor-specific humoral response. In chronically rejected lung allografts, B cells contribute to the formation of tertiary lymphoid structures and promote local alloimmune responses. However, B cells are functionally heterogeneous and some B cell subsets may promote alloimmune tolerance. In this review, we describe the current understanding of B-cell-dependent mechanisms in pulmonary allograft rejection and highlight promising future strategies that employ B cell-targeted therapies.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8934882PMC
http://dx.doi.org/10.3389/fimmu.2022.845867DOI Listing

Publication Analysis

Top Keywords

allograft rejection
8
cell immunity
4
immunity lung
4
lung transplant
4
transplant rejection
4
rejection effector
4
effector mechanisms
4
mechanisms therapeutic
4
therapeutic implications
4
implications allograft
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!